Determination of cyclosporine A by the fluorescence polar-ization immunoassay methods in renal transplant recipients and the influence of hepatic function on CsA concentration

Abstract

Abstract: Aim This study was to investigate the influence of specific and nonspecific detecting methods on CsA blood concentration in renal transplanting patients, and to observe the effects of hepatic function on CsA concentration. Methods Eighty-four whole blood specimens from 36 renal transplant recipients who had received cyclosporine (CsA) were measured with MAFPIA and PAFPIA. Results Linear regression analysis showed that there was a better rela tionship between PAFPIA and MAFPIA (r = 0.8974). Values of PAFPIA in patients with reduced hepatic function was significantly higher than those of MAFPIA. Both regression curve parameters differed greatly from each other. It is suggested that therapeutic drug monitoring for CsA should be performed with the specific method.

Key words: Cyclosporine A, Fluorescence polyriza tion immunoassay, Blood concentration

CLC Number:

R969

Wang Feng, Zhang Huafeng, Li Ying, Su Shiping, Sun Bin. Determination of cyclosporine A by the fluorescence polar-ization immunoassay methods in renal transplant recipients and the influence of hepatic function on CsA concentration[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1996, 1(1): 13-16.

References

1 Faulds D, Goa KL Benfield P. Cyclosporin:areview of its pharmacodynamic and pharmacokinetic properties, and therapeulic use in immunoregulatory disorders. Drugs, 1993, 45:953
2 Tjandrea-Maga B, Verbessel R, Scharpe S, e1 al. Comparison of cyclosporin A measurement in whole blood by six different methods. J Clin Chem Clin Biochem, 1990, 28:53
3 Kahan BD,Grevel J. Oplimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation, 1988, 46:631
4 Grevel J, Welsh MS,Kaham BD. Cyclosporine monitoring in renal transplanlation area under the curve monitoring is superior to trough - level monitoring. Ther Drug Monit, 1989, 11:246
5 Mraz W,Muller C,Monlar B,et al. Analysis oJ cyclosporin A (CsA) concentrations by fluorescence po-larization immunoassay (FPIA):comparison with radio immunoassay (RIA) and liquid chromalography (HPLC). Tranplant Proc, 1989,21:885
6 Sanghvi A,Diven WF,Warly VS,et al. Cy-closporine measurement by FPIA utilizing abboll TDx instrumenl. Transplant Proc, 1989, 21:898
7 Napoli KL, Kahan BD. Nonseleclive measuremenl of cyclosporine for therapeulic drug monitoring by fluores-cence polarization immunoassay with a rabbit polyclonal antibody:I. Evaluation of the serum methodology and comparison with a sheep polyclonal antibody in an ³H-trancer mediated radioimmunoassay. Tranplant Proc, 1990, 22:1175
8 Vine W, Bowers LD. Cyclosporine:Structure, phar-macokinetics, and therepeutic drug monitoring. Crit Rev Clin Lab Sci,1987, 25:275
9 Lindholm A. Faclors influencing the pharmacokine1-ics of cyclosporine in man. Ther Drug Monit, 1991, 13:465
10 Lensmeyer GL,Wlebe RA,et al. Distribulion of cyclosporine A melabolites among plasma and cells in whole blood:Effect of temperature, Hemalocrit, and metabolite concentralion. Clin Chem,1989,35:56
11 Yee GC. Recent advances in cyclosporine phnrma-cokinetics. Pharmacotherapy, 1991,11:130s
12 Hartman NR,Jardine l. The in vilro activitv, ra-dioimmunoassay crossreactivity, and molecular weight of thirteen. Drug Metab Dispos, 1987, 15:661
13 Freeman DJ. Pharmacology and pharniacokinetics of cyclosporine. Clin Biochem,1991,24:9

[1]	DU Wenpeng, AO Jiangen, TAO Yi, WU Guansheng, HE Jiake. Study on the factors affecting the steady-state blood concentration of tacrolimus in patients with autoimmune diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 645-651.
[2]	SUN Qing, SUN Jianfang, LI Li, CHANG Huichao, ZHOU Quan. Effects of Wuzhi capsule on the pharmacokinetics of simvastatin and its metabolite simvastatin acid in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1242-1249.
[3]	LIU Tingting, YU Wei, YANG Chunlan, SHUAI Zongwen, GAO Beibei, XIA Quan. Blood concentration monitoring of hydroxychloroquine in patients with autoimmune diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1359-1363.
[4]	MENG Xiang-guang, NI Wen-qiong, WANG Chao, MA Deng-xuan, LI Zhi, ZHOU Hong-hao. Advances in pharmacogenetics of systemic therapies for psoriasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(11): 1307-1313.
[5]	LI Qing, XIN Hua-wen, WU Xiao-chun, YU Ai-rong, XIONG Lei. Clinical study for the effects of Wuzhi-capsule on blood concentration of tacrolimus in renal transplant recipients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(7): 804-807.
[6]	PANG Xiao-yun, SHEN Jin-fang. Influence of planta medica on the blood concentration of tacrolimus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(1): 110-112.
[7]	ZHANG Qing, CHEN Hong, ZHANG Li, TIAN Yan, NIU Yu-jian, LI Qin, CHEN Xin-guo, ZANG Yun-jin, SHEN Zhong-yang. Evaluation of tacrolimus combining with liver-aid tablet in the treatment of acute rejection after liver transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(11): 1286-1290.
[8]	WU Jing, WANG Ben-jie, WEI Chun-min, KONG Xiang-lin, GUO Rui-chen. Determination of paeonol in human plasma by HPLC and its pharmacokinetic studies [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(8): 935-938.
[9]	WU Li-ping, LI Qi-xiong. Protective effects of quercetin on nephrotoxicity induced by cyclosporine A in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(6): 659-667.
[10]	ZHENG Zhuan-jie, FANG Yi, WANG Rui. Measurement of recombinant human glucagon-like peptide-1 (7-36) concentration by ELISA kit methods [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(4): 444-447.
[11]	ZHANG Ya-tong, YANG Li-ping, SHAO Hong, LI Ke-xin, SUN Chun-hua, SHI Lu-wen. Effects of different formulations of cyclosporine A on trough blood concentration in patients with myasthenia gravis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(8): 871-875.
[12]	ZHANG Ya-tong, YANG Li-ping, SHAO Hong, Li Ke-xin, SUN Chun-hua, SHI Lu-wen. Effects of MDR1 gene C3435T polymorphism on pharmacokinetics of cyclosporine A in myasthenia gravis patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(2): 133-136.
[13]	SUN Cheng-Chun, ZHAO Xiao-Yuan, CAO Yang, WANG Jing-Xiang. Effect of clarithromycin on pharmacokinetics of aminophylline at steady state in rabbits [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(1): 21-23.
[14]	DONG Ya-Lin, WANG Mao-Yi, HUANG Meng, TIAN Pu-Xun, PANG Sheng-Qiang. Clinical use of mycophenolate mofetil in renal taransplation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1999, 4(4): 313-315.
[15]	SUN Cheng-Chun, ZHANG Li, WANG JingXiang. Effect of ketoconazole on concentration and Pharmacokinetics of aminophyllin in blood [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1998, 3(1): 38-40.